Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Both AD and dyslipidemias are global public health problems
2023-04-20

Both AD and dyslipidemias are global public health problems, and an increase in their incidence over the next decades is expected. Among many triggering elements, the increase in life expectancy is one of the main risk factors associated with the increase in the incidence of AD. Meanwhile, dyslipide
-
Some of the studies reported
2023-04-19

Some of the studies reported elevated ADA levels in schizophrenia patients (SZ) undergoing treatment with antipsychotics (Dutra et al., 2010; Brunstein et al., 2007; Ghaleiha et al., 2011). However, it is unclear whether the increased serum ADA reported in these studies was the consequence of treatm
-
Two patients developed diffuse mesangio proliferative
2023-04-19

Two patients developed diffuse mesangio-proliferative glomerulonephritis (DMPG) postoperatively, presenting as nephrotic syndrome and benign haematuria, respectively. DMPG has been reported in an adult patient with thymomatous MG following thymectomy [35], and various types of glomerulonephritis hav
-
The first natural product described as LO inhibitor was the
2023-04-19

The first natural product described as 5-LO inhibitor was the polyphenol nordihydroguaiaretic kl compound name receptor from the Mexican dessert plant Larrea divaricata in 1981 (Bokoch and Reed, 1981), short after the initial identification of 5-LO in 1979 (Borgeat and Samuelsson, 1979). Long time
-
Poziotinib br Material and methods br Results br Discussion
2023-04-19

Material and methods Results Discussion Clinical gene therapy trials with viral vectors have been in use for treatment of various genetic disorders and diseases, however efficacious, targetable and highly reliable non-viral delivery systems are needed for safe and long-term applications. De
-
AZ5104 br Identification of the kinase that phosphorylates P
2023-04-19

Identification of the kinase that phosphorylates P450c17 The first Ser/Thr kinase that phosphorylates P450c17 was identified only recently. Of the 518 kinases in the human ‘kinome’ 278 are Ser/Thr kinases (Manning et al., 2002), but microarrays identified only 145 Ser/Thr kinases in human NCI-H29
-
AZ5104 br Identification of the kinase that phosphorylates P
2023-04-19

Identification of the kinase that phosphorylates P450c17 The first Ser/Thr kinase that phosphorylates P450c17 was identified only recently. Of the 518 kinases in the human ‘kinome’ 278 are Ser/Thr kinases (Manning et al., 2002), but microarrays identified only 145 Ser/Thr kinases in human NCI-H29
-
Although several different membrane estrogen receptors have
2023-04-18

Although several different membrane estrogen receptors have been reported (Qiu et al., 2008; Revankar et al., 2005), a large percentage of membrane-initiated steroid hormone signaling appears to be performed by a subpopulation of the same receptors that act in the nucleus. Specifically, estrogen rec
-
Dual acting RAAS blockade and neprilysin inhibition has been
2023-04-17

Dual-acting RAAS blockade and neprilysin inhibition has been evaluated in several clinical HF trials. In PARADIGM-HF [6,7], LCZ696 was superior to enalapril in reducing mortality and HF hospitalizations in symptomatic patients with HF with reduced EF. Augmented benefits on maladaptive cardiac remode
-
We found that decreased Ng levels lead to a lower
2023-04-17

We found that decreased Ng levels lead to a lower threshold for LTD induction at L4–L2/3 synapses. Previous studies in hippocampal slice culture have shown that LTD at individual synapses induces spine elimination at both the targeted synapse and selective neighboring synapses when spines are monito
-
Here we provide evidence that NO contributes
2023-04-17

Here, we provide evidence that NO contributes to changes in synaptic strength, but also offer an explanation as to why previous attempts to link NO to LTP have often failed. Our results describe a model by which cycling AMPARs, held in intracellular pools, are rapidly delivered to the membrane surfa
-
A central question that arises
2023-04-17

A central question that arises in this discussion is whether enhanced neurobehavioral responses to food cues emerge as a consequence of weight gain, or whether there are intrinsic differences in the motivational responses to food cues that precede weight gain. In support of pre-existing differences,
-
Tissue distribution showed that ctrp was abundantly expresse
2023-04-17

Tissue distribution showed that ctrp9 was abundantly expressed in the kidney of male and female tilapia. In mice, the Ctrp9 was identified in adipose tissue, and the expression levels were higher in females than that of males (Wong et al., 2009). Recent studies indicated that Ctrp9 was also expresse
-
naloxone hydrochloride Pituitary adenylate cyclase activatin
2023-04-17

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the secretin/growth hormone-releasing hormone (GHRH)/vasoactive intestinal peptide (VIP) family, with potent anti-inflammatory and potent cytoprotective properties [[6], [7], [8], [9], [10], [11], [12], [13]]. PACAP exists as
-
br Concluding remarks ROP is a major cause of childhood
2023-04-17

Concluding remarks ROP is a major cause of childhood blindness in the world. Current pharmacological therapy focus on anti-VEGF strategy, but this strategy is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants. Preclinical studies u
8531 records 371/569 page Previous Next First page 上5页 371372373374375 下5页 Last page